Background: Newborns with ductal-dependent congenital heart disease (CHD) are at increased risk for developing necrotizing enterocolitis (NEC). Objectives: To investigate whether the use of dual-strain probiotics is beneficial for prevention of NEC in CHD patients, as demonstrated for premature infants. Study Design: Single-center retrospective cohort study of newborns with ductal-dependent CHD before and after implementation of oral dual-strain probiotics containing Bifidobacterium infantis and Lactobacillus acidophilus, on each day of exposure to prostaglandin E1 (PGE1). Results: Birth weight, gestational age, and distribution of heart defects were similar in both cohorts. NEC occurred in 6 of 247 (2.4%) patients without probiotics, and in 3 of 242 (1.2%) patients who received probiotics (p = 0.504). NEC-related mortality (0.4 vs. 0.4%, p = 1.000) and overall mortality (11.0 vs. 8.7%, p = 0.448) were likewise not different. PGE1 exposure was 1,788 and 2,455 days, respectively. In subgroup analysis of 152 infants with aortic arch malformations, such as coarctation of the aorta and interrupted aortic arch, we observed a significant reduction of NEC frequency (5.6 vs. 0.0%, p = 0.048). Conclusions: This is the first study to investigate the effect of a dual-strain probiotic on NEC in CHD patients. Infants with aortic arch malformations appear to benefit from dual-strain probiotics. Due to the scarcity of concurrence of ductal-dependent CHD and NEC, a clinical trial on probiotics to decrease risk of NEC in infants with ductal-dependent CHD would require several thousand infants.

1.
Lin
PW
,
Stoll
BJ
.
Necrotising enterocolitis
.
Lancet
.
2006
Oct
;
368
(
9543
):
1271
83
.
[PubMed]
0140-6736
2.
McElhinney
DB
,
Hedrick
HL
,
Bush
DM
,
Pereira
GR
,
Stafford
PW
,
Gaynor
JW
, et al.
Necrotizing enterocolitis in neonates with congenital heart disease: risk factors and outcomes
.
Pediatrics
.
2000
Nov
;
106
(
5
):
1080
7
.
[PubMed]
0031-4005
3.
Motta
C
,
Scott
W
,
Mahony
L
,
Koch
J
,
Wyckoff
M
,
Reisch
J
, et al.
The association of congenital heart disease with necrotizing enterocolitis in preterm infants: a birth cohort study
.
J Perinatol
.
2015
Nov
;
35
(
11
):
949
53
.
[PubMed]
0743-8346
4.
Lau
PE
,
Cruz
SM
,
Ocampo
EC
,
Nuthakki
S
,
Style
CC
,
Lee
TC
, et al.
Necrotizing enterocolitis in patients with congenital heart disease: A single center experience
.
J Pediatr Surg
.
2018
May
;
53
(
5
):
914
7
.
[PubMed]
0022-3468
5.
Luce
WA
,
Schwartz
RM
,
Beauseau
W
,
Giannone
PJ
,
Boettner
BL
,
Cheatham
JP
, et al.
Necrotizing enterocolitis in neonates undergoing the hybrid approach to complex congenital heart disease
.
Pediatr Crit Care Med
.
2011
Jan
;
12
(
1
):
46
51
.
[PubMed]
1529-7535
6.
Siano
E
,
Lauriti
G
,
Ceccanti
S
,
Zani
A
.
Cardiogenic Necrotizing Enterocolitis: A Clinically Distinct Entity from Classical Necrotizing Enterocolitis
.
Eur J Pediatr Surg
.
2019
Feb
;
29
(
1
):
14
22
.
[PubMed]
0939-7248
7.
Neu
J
,
Walker
WA
.
Necrotizing enterocolitis
.
N Engl J Med
.
2011
Jan
;
364
(
3
):
255
64
.
[PubMed]
0028-4793
8.
Martin
CR
,
Walker
WA
.
Probiotics: role in pathophysiology and prevention in necrotizing enterocolitis
.
Semin Perinatol
.
2008
Apr
;
32
(
2
):
127
37
.
[PubMed]
0146-0005
9.
AlFaleh
K
,
Anabrees
J
.
Probiotics for prevention of necrotizing enterocolitis in preterm infants
.
Cochrane Database Syst Rev
.
2014
Apr
;(
4
):
CD005496
.
[PubMed]
1469-493X
10.
Dermyshi
E
,
Wang
Y
,
Yan
C
,
Hong
W
,
Qiu
G
,
Gong
X
, et al.
The “Golden Age” of Probiotics: A Systematic Review and Meta-Analysis of Randomized and Observational Studies in Preterm Infants
.
Neonatology
.
2017
;
112
(
1
):
9
23
.
[PubMed]
1661-7800
11.
Bubberman
JM
,
van Zoonen
A
,
Bruggink
JL
,
van der Heide
M
,
Berger
RM
,
Bos
AF
, et al.
Necrotizing Enterocolitis Associated with Congenital Heart Disease: a Different Entity?
J Pediatr Surg
.
2019
Sep
;
54
(
9
):
1755
60
.
[PubMed]
0022-3468
12.
Ellis
CL
,
Rutledge
JC
,
Underwood
MA
.
Intestinal microbiota and blue baby syndrome: probiotic therapy for term neonates with cyanotic congenital heart disease
.
Gut Microbes
.
2010
Nov-Dec
;
1
(
6
):
359
66
.
[PubMed]
1949-0976
13.
Umenai
T
,
Shime
N
,
Asahara
T
,
Nomoto
K
,
Itoi
T
.
A pilot study of Bifidobacterium breve in neonates undergoing surgery for congenital heart disease
.
J Intensive Care
.
2014
Jun
;
2
(
1
):
36
.
[PubMed]
2052-0492
14.
Karpen
HE
.
Nutrition in the Cardiac Newborns: Evidence-based Nutrition Guidelines for Cardiac Newborns
.
Clin Perinatol
.
2016
Mar
;
43
(
1
):
131
45
.
[PubMed]
0095-5108
15.
Alfaleh
K
,
Bassler
D
.
Probiotics for prevention of necrotizing enterocolitis in preterm infants
.
Cochrane Database Syst Rev
.
2008
Jan
;(
1
):
CD005496
.
[PubMed]
1469-493X
16.
Guthmann
F
,
Arlettaz Mieth
RP
,
Bucher
HU
,
Bührer
C
.
Short courses of dual-strain probiotics appear to be effective in reducing necrotising enterocolitis
.
Acta Paediatr
.
2016
Mar
;
105
(
3
):
255
9
.
[PubMed]
0803-5253
17.
Bell
MJ
,
Ternberg
JL
,
Feigin
RD
,
Keating
JP
,
Marshall
R
,
Barton
L
, et al.
Neonatal necrotizing enterocolitis. Therapeutic decisions based upon clinical staging
.
Ann Surg
.
1978
Jan
;
187
(
1
):
1
7
.
[PubMed]
0003-4932
18.
Penders
J
,
Thijs
C
,
Vink
C
,
Stelma
FF
,
Snijders
B
,
Kummeling
I
, et al.
Factors influencing the composition of the intestinal microbiota in early infancy
.
Pediatrics
.
2006
Aug
;
118
(
2
):
511
21
.
[PubMed]
0031-4005
19.
Rose
AT
,
Patel
RM
.
A critical analysis of risk factors for necrotizing enterocolitis
.
Semin Fetal Neonatal Med
.
2018
Dec
;
23
(
6
):
374
9
.
[PubMed]
1744-165X
20.
Becker
KC
,
Hornik
CP
,
Cotten
CM
,
Clark
RH
,
Hill
KD
,
Smith
PB
, et al.
Necrotizing enterocolitis in infants with ductal-dependent congenital heart disease
.
Am J Perinatol
.
2015
Jun
;
32
(
7
):
633
8
.
[PubMed]
0735-1631
21.
Carlo
WF
,
Kimball
TR
,
Michelfelder
EC
,
Border
WL
.
Persistent diastolic flow reversal in abdominal aortic Doppler-flow profiles is associated with an increased risk of necrotizing enterocolitis in term infants with congenital heart disease
.
Pediatrics
.
2007
Feb
;
119
(
2
):
330
5
.
[PubMed]
0031-4005
22.
DeWitt
AG
,
Charpie
JR
,
Donohue
JE
,
Yu
S
,
Owens
GE
.
Splanchnic near-infrared spectroscopy and risk of necrotizing enterocolitis after neonatal heart surgery
.
Pediatr Cardiol
.
2014
Oct
;
35
(
7
):
1286
94
.
[PubMed]
0172-0643
23.
Stapleton
GE
,
Eble
BK
,
Dickerson
HA
,
Andropoulos
DB
,
Chang
AC
.
Mesenteric oxygen desaturation in an infant with congenital heart disease and necrotizing enterocolitis
.
Tex Heart Inst J
.
2007
;
34
(
4
):
442
4
.
[PubMed]
0730-2347
24.
Xing
J
,
Ying
Y
,
Mao
C
,
Liu
Y
,
Wang
T
,
Zhao
Q
, et al.
Hypoxia induces senescence of bone marrow mesenchymal stem cells via altered gut microbiota
.
Nat Commun
.
2018
May
;
9
(
1
):
2020
.
[PubMed]
2041-1723
25.
Ellis
CL
,
Bokulich
NA
,
Kalanetra
KM
,
Mirmiran
M
,
Elumalai
J
,
Haapanen
L
, et al.
Probiotic administration in congenital heart disease: a pilot study
.
J Perinatol
.
2013
Sep
;
33
(
9
):
691
7
.
[PubMed]
0743-8346
26.
Dilli
D
,
Aydin
B
,
Zenciroğlu
A
,
Özyazici
E
,
Beken
S
,
Okumuş
N
.
Treatment outcomes of infants with cyanotic congenital heart disease treated with synbiotics
.
Pediatrics
.
2013
Oct
;
132
(
4
):
e932
8
.
[PubMed]
0031-4005
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.